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Abstract
Background and aims: Back and joint pain are the most common extraintestinal symptoms reported 
by patients with inflammatory bowel disease (IBD). We assessed the impact of back/joint pain, 
illness perceptions, and coping on quality of life (QOL) and work productivity in patients with IBD.
Methods: Our cohort included 155 IBD patients with and 100 without arthropathy. Arthropathy was 
defined as daily back pain for ≥3 months and/or peripheral joint pain and/or joint swelling over the 
last year. At baseline and at 12 months, patients completed questionnaires on the extent of back/
joint pain, IBD disease activity, illness perceptions, coping, QOL, and work productivity. The impact 
of back/joint pain, illness perceptions and coping on QOL and work productivity was determined, 
using linear mixed models.
Results: In total, 204 IBD patients (72% Crohn’s disease, 40% male, mean age 44  ±  14  years) 
completed questionnaires at both time points. At both time points, IBD patients with back/joint 
pain reported a significantly lower QOL and work productivity compared with IBD patients without 
back/joint pain. Predictors of low QOL were back/joint pain (β  = −1.04, 95% confidence interval 
[CI] −1.40, −0.68), stronger beliefs about the illness consequences (β = −0.39, 95% CI −0.59, −0.18) 
and emotional impact of IBD (β = −0.47, 95% CI −0.66, −0.28), and the coping strategy ‘decreasing 
activity’ (β  =  −0.26, 95% CI −0.48, −0.03). Predictors of work productivity were back/joint pain 
(β = 0.22, 95% CI 0.07, 0.37) and illness consequences (β = 0.14, 95% CI 0.06, 0.22).
Conclusion: Back/joint pain, illness perceptions, and coping are significant predictors of QOL and 
work productivity, after controlling for disease activity.
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1. Introduction
Arthropathies are the most common extraintestinal manifestations 
in patients with inflammatory bowel disease (IBD), with prevalence 
rates ranging between 1 and 46%.1–10 In general, arthropathies affect 
young IBD patients at the peak of their working life and are there-
fore potentially associated with high morbidity and increased costs.11
IBD-associated arthropathy is considered a subtype of spondy-
larthropathy and may involve both peripheral and axial joints. Back 
and joint pain (hereafter referred to as ‘back/joint pain’) are the most 
important clinical manifestations of IBD-associated arthropathy.
Although back/joint pain is major problem in the general popu-
lation,12 data on the impact of back/joint pain on the quality of life 
(QOL) and work disability in patients with IBD are scarce. According 
to a population-based study3 and a cross-sectional study,4 QOL was 
significantly reduced in IBD patients with non-inflammatory joint 
pain and self-reported arthritis, respectively. Yet the impact of back/
joint pain on work productivity and the relationships between back/
joint pain, illness perceptions, coping, and important outcomes such 
as QOL and work productivity has not been assessed before.3,4
It has been shown clearly that QOL and other health outcomes 
are associated not only with the disease itself, but also with factors 
such as illness perceptions and coping. The relationships between 
disease characteristics, illness perceptions, coping, and health out-
come are supported by the Common Sense Model.13,14 According to 
this model, patients generate both cognitive and emotional repre-
sentations (known as illness perceptions) in response to a perceived 
health threat or illness. Illness perceptions provide a framework for 
patients to make sense of their symptoms and create a coherent view 
of their illness. This in turn guides coping strategies, such as decreas-
ing or pacing activities, with potential impact on health outcomes 
such as QOL and work productivity. Thus, the impact of illness 
perceptions on health outcomes may be attenuated by adopting a 
certain coping strategy.
The efficacy and validity of the Common Sense Model has been 
shown in patients with various chronic illnesses, such as rheuma-
toid arthritis and multiple sclerosis.15,16 Previous studies in IBD have 
also found strong relationships between illness perceptions, coping, 
and various health outcomes, including QOL, psychological distress 
(depression and anxiety), sexual health, and disability.17–25
Improving our understanding of the relationships between back/
joint pain, illness perceptions, and coping behaviors in patients with 
IBD may provide possible targets for biopsychosocial interventions 
aimed at reducing morbidity and costs and increasing patients’ QOL.
In this prospective study we aimed to examine the impact of 
back/joint pain, illness perceptions, and coping on QOL and work 
productivity in a carefully selected group of IBD patients, after con-
trolling for demographic and clinical characteristics.
2. Materials and methods
2.1. Patient population and study design
Between July 2009 and February 2010, 258 IBD patients were 
systematically assessed by a multidisciplinary team of gastroen-
terologists and rheumatologists at the JOINT outpatient clinic of 
the Leiden University Medical Centre. The systematic assessment 
consisted of a medical history (extraintestinal manifestations, medi-
cation use), physical examination (distribution of painful joints, 
enthesitis,26 dactylitis26), laboratory tests (C-reactive protein, eryth-
rocyte sedimentation rate, HLA-B27), and signs of sacroiliitis on 
X-ray (optional).27 Based on this assessment 155 (60.1%) patients 
with and 100 (38.8%) patients without arthropathy were identified. 
Arthropathy was defined as chronic back pain for at least 3 months, 
and/or peripheral joint pain/swelling at presentation or during 
the previous year. Three patients (1.1%) with fibromyalgia were 
excluded.
Patients were then prospectively followed for 12  months. At 
baseline and at 12 months of follow-up, patients completed a web-
based or postal questionnaire covering demographic characteristics 
(age, gender, and working status), the presence and extent of back/
joint pain, illness perceptions, coping strategies, QOL, work produc-
tivity, and activity impairment (see below). Variables concerning IBD 
subtype and the Montréal classification were obtained from medical 
records.
As we were primarily interested in the impact of current back/
joint paint on QOL and work productivity, the patient popula-
tion was divided into patients with and without back/joint pain as 
reported at baseline. Obviously, as we relied on self-reported data, 
the presence of joint swelling could not be ascertained.
The study was centrally approved by the Ethics Committee of the 
Leiden University Medical Centre. All patients an signed informed 
consent form.
2.3. Predictors
2.3.1. Back/joint pain and IBD clinical disease activity
Back/joint pain was quantified using two 11-point numeric rating 
scales, one for back pain and one for joint pain, ranging from 0 (‘no 
back/joint pain’) to 10 (‘worst imaginable back/joint pain’) during 
the previous week. The mean score was used for patients reporting 
both back and joint pain. Clinical IBD activity was measured with 
the well-validated Harvey–Bradshaw Index (10 items, excluding the 
question about abdominal mass)27 and the Simple Clinical Colitis 
Activity Index (nine items)28 for patients with Crohn’s disease (CD) 
and ulcerative colitis (UC), respectively. A score >4 indicated active 
disease.
2.3.2. Illness perceptions
Illness perceptions were measured with the Revised Illness Perception 
Questionnaire (IPQ-R).29 For the present study, eight subscales of 
the IPQ-R were used: Illness identity (number of symptoms that 
patients associate with IBD); Timeline chronic (expected duration 
of IBD); Timeline cyclical (expected cyclical symptomatology of 
IBD); Consequences (negative consequences for the patients’ lives); 
Personal control (perceived personal control over IBD); Treatment 
control (perceived efficacy of treatment); Emotional representations 
(negative emotions resulting from IBD); and Coherence (personal 
understanding of IBD). The Illness identity subscale is calculated by 
summing the symptoms (range 0–14) that patients associate with 
IBD. For the other subscales items are rated on a five-point Likert 
scale (from ‘strongly disagree’ to ‘strongly agree’). To facilitate inter-
pretation of these subscales, mean scores are presented. Subscales 
showed a high internal reliability (Cronbach’s α ranging from 0.76 
to 0.89), except for the Treatment control subscale (0.59), which was 
therefore excluded from further analysis.
2.3.3.  Coping
Coping was measured with the COping with Rheumatic Stressors 
questionnaire (CORS), covering eight coping strategies directed at 
the most important stressors of immune-mediated inflammatory 
disease (e.g. IBD), including pain, limitations, and dependency.30,31 
Coping strategies directed at pain included Comforting cognitions 
(self-encouragement, putting the pain into perspective; nine items), 
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Decreasing activities (eight items), and Diverting attention (thinking 
about something nice; eight items). Coping strategies directed at lim-
itations included Optimism (five items), Pacing (adapting one’s level 
of activity; 10 items), and Creative solution seeking (finding crea-
tive solutions to cope with limitations in work, household activities, 
leisure time, and hobbies; eight items). Coping strategies directed at 
dependency included Accepting (making an effort to accept one’s 
level of dependency; six items) and Consideration (thoughtful con-
cern for others; seven items). For each item, patients reported how 
often they employed a particular coping strategy (1  =  ‘seldom or 
never’, 2 = ‘sometimes’, 3 = ‘often’, 4 = ‘very often’). Higher scores 
indicate more frequent use of a particular coping strategy. Internal 
reliability within the subscales was high (Cronbach’s α ranging from 
0.78 to 0.86).
2.3.4. Health outcomes: QOL, work productivity, and activity 
impairment
The QOL was measured with both a disease-specific and a generic 
questionnaire. The Short Inflammatory Bowel Disease Questionnaire 
(SIBDQ) was developed as a short version of the IBDQ, and is a 
simple, validated 10-item questionnaire that assesses disease-specific 
QOL of patients with IBD.32,33 Total scores range from 10 to 70, 
with a higher score indicating better QOL. The Short-Form 36 (SF-
36) is a generic questionnaire comprising 36 items, grouped within 
a Physical Component Score (PCS) and a Mental Component Score 
(MCS).34 The PCS consist of physical functioning, role of limitations 
due to physical health problems, bodily pain, and general health 
perception. The MCS consists of vitality, social function, role limi-
tations due to personal or emotional problems, and mental health. 
Each component score has a score ranging from 0 to 100, with a 
high score indicating better functional status.
The Work Productivity and Activity Impairment questionnaire 
(WPAI) assesses the impact of IBD on work productivity and daily 
activities during the previous 7 days.35,36 It generates four component 
scores: percentage of work time missed (absenteeism); percentage 
of impairment while working (presenteeism); percentage of over-
all work impairment (absenteeism and presenteeism combined); 
and percentage of activity impairment. Unemployed patients only 
answered questions relating to employment status and activity 
impairment. Scores for WPAI range from 0% (‘no impairment’) to 
100% (‘total loss of work productivity/activity’).
2.4. Statistics
Data analyses were performed using SPSS 20.0 and SAS 9.2. 
Descriptive statistics were used to characterize CD and UC patients. 
Means and medians were reported with a standard deviation (SD) 
and interquartile range (IQR), respectively. Mean baseline differ-
ences with regard to QOL, work productivity, and activity impair-
ment between patients with and without back/joint pain were 
determined using the paired Student’s t-test. Univariate analyses 
were performed to assess associations between back/joint pain, ill-
ness perceptions, coping, and outcomes, including QOL, work pro-
ductivity, and activity impairment. To correct for multiple testing, 
the level of significance was set at p < 0.007 (0.05/7) and p < 0.006 
(0.05/8) for the illness perceptions (seven IPQ-R subscales) and 
coping (eight CORS subscales), respectively. Linear mixed models 
with random intercept were used to assess the independent effects 
of back/joint pain, illness perceptions, and coping on QOL, work 
productivity, and activity impairment. Independent variables that 
reached significance in univariate analyses were included. Based 
on previous data,37 gender and disease activity were included as 
covariates. To assess whether back/joint pain, illness perceptions, 
and coping contributed to the variance of outcomes, multiple linear 
mixed models were used. With the Common Sense Model as the 
theoretical framework, back/joint pain was entered in the first step, 
illness perceptions in the second step, and coping strategies in the 
third step. The likelihood ratio test (difference of −2 log likelihood 
between two steps) was performed to assess whether each step sig-
nificantly improved our model.
3. Results
3.1. Baseline characteristics of study population
The baseline questionnaire was completed by 245/255 patients 
(response rate 96.1%), of whom 204 also completed the follow-up 
questionnaire at 12 months (loss to follow-up 16.7%) (Figure 1). 
Thus, the 204 patients who completed questionnaires at both time 
points constituted our study population.
 Of the 204 patients, 146 (71.6%) had CD and 58 (28.4%) had 
UC, with a mean age of 44.3 (SD 13.7) years and a median dis-
ease duration of 15.0 (IQR 7.0–24.0) years (Table 1). In CD, ileoco-
lonic disease (65/146; 44.5%), and inflammatory behavior (62/146; 
42.5%) were the most common disease phenotypes. In UC, pan-
colitis (34/58; 58.6%) was the dominant disease phenotype. Based 
on the numeric rating scale, back/joint pain was present in 113/204 
(55.4%) patients, of whom 41 (36.3%) had peripheral joint pain, 
8 (7.1%) had back pain, and 64 (56.6%) had mixed complaints. 
At physical examination, 45/105 (42.9%) patients with peripheral 
or mixed joint complaints had four or more tender joints (polyar-
ticular). Enthesitis was present in 2 (1.0%) patients, dactylitis in 2 
(1.0%), and extraintestinal manifestations in 49 (24.0%) patients. 
Further investigations revealed an elevated C-reactive protein in 
30 (14.7%) patients, elevated erythrocyte sedimentation rate in 42 
(20.9%), HLA-B27 seropositivity in 7/118 (5.9%), and sacroiliitis 
on X-ray in 5/123 (4.1%) patients.
Online Supplementary Material A shows data on baseline demo-
graphic and clinical variables in completers and noncompleters. 
There were no relevant statistically significant differences between 
the two groups, except that noncompleters had a significantly 
younger mean age (38.4 versus 44.3 years, p = 0.011).





n = 3 (1.1%)
Without
arthropathies
n = 100 (38.8%)
With arthropathies
n = 155 (60.1%)
Patients completed baseline
questionnaire
n = 245 (96.1%)
Patients completed
12-month questionnaire
n = 204 (83.3%)
Loss to follow-up
n = 41 (16.7%)
Figure 1. Study flow-chart.
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3.2.  Baseline levels of quality of life, work, and 
activity impairment
Patients with IBD who had back/joint pain had significantly lower lev-
els of disease-specific QOL (SIBDQ 47.8 ± 10.7 versus 55.1 ± 8.7) and 
generic QOL (SF-36–PCS 41.9  ±  8.9 versus 52.1  ±  7.6; SF-36–MCS 
45.1 ± 10 versus 48.7 ± 8.6) at baseline compared with IBD patients with-
out back/joint pain (Figure 2). Additionally, IBD patients with back/joint 
pain had significantly higher levels of work impairment (45.0 ± 9.9 versus 
22.0 ± 3.3) and activity impairment (37.0 ± 8.1 versus 19.0 ± 2.9) at 
baseline compared with IBD patients without back/joint pain (Figure 2).
3.3 Predictors of QOL and work activity 
impairment
Based on the univariate analyses (Online Supplementary Material 
B), each of the illness perceptions and coping strategies were signifi-
cantly associated with QOL, work impairment, and activity impair-
ment and were therefore included in multiple linear mixed models. 
Clinical disease activity was significantly associated with back/joint 
pain (β = 2.04, p < 0 .00), with a variance inflation factor of 1.00, 
indicating no multicollinearity.
In the first step of our multivariate model we assessed whether 
back/joint pain was associated with disease-specific QOL (SIBDQ), 
generic QOL (SF-36–PCS and SF-36–MCS), work impairment, and 
activity impairment (Tables 2–4), while controlling for gender and 
IBD activity. Back/joint pain was significantly associated with SIBDQ 
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Figure 2. Mean baseline levels of generic quality of life (SF-36–PCS, SF-36–
MCS), disease-specific quality of life (SIBDQ), Work and Activity Impairment 
(WPAI) in IBD patients with (n = 113) and without (n = 91) joint pain.
Table 2. Linear mixed model with SIBDQ as outcome variable and 
demographic/clinical variables (step 1), illness perceptions (step 
2), and coping (step 3) as independent variables.
Predicting variables Quality of life
β 95% CI
Step 1: demographic and clinical variables
 Disease activity −1.17*** −1.41, −0.93
 Joint pain −1.04*** −1.40, −0.68
Step 2: illness perceptions
 Identity −0.17 −0.48, 0.14
 Consequences −0.39*** −0.59, −0.18
 Personal control −0.08 −0.27, 0.10
 Illness coherence 0.14 −0.08, 0.35
 Timeline cyclical −0.36** −0.63, −0.10
 Emotional representations −0.47*** −0.66, −0.28
Step 3: coping
 Decreasing activity −0.26* −0.48, −0.03
 Pacing 0.11 −0.06, 0.28
Results of linear mixed model showing the independent influence of predict-
ing variables on SIBDQ, represented as β = coefficients. These coefficients refer 
to how many standard deviations SIBDQ will change per standard deviation 
increase in the predicting variable.
*p < 0.05; **p < 0.01; ***p < 0.001.
Table 1. Demographic and clinical variables of the study population.
Variable IBD (n = 204)
Type of IBD, n (%)
 Crohn’s disease 146 (71.6)
 Ulcerative colitis 58 (28.4)
Age (years), mean (SD) 44.3 (13.7)
Male gender, n (%) 82 (40.2)
Current smoker, n (%) 47 (23.0)
Disease duration (years), median (IQR) 15.0 (7.0–24.0)
Employed, n (%) 128 (62.2)
Montreal classification
 Location of CD, n (%)
  L1 ileal 36 (24.7)
  L2 colonic 33 (22.6)
  L3 ileocolonic 65 (44.5)
  L1–3 + L4 upper 12 (9.5)
 Behavior of CD, n (%)
  B1 non-stricturing/penetrating 62 (42.5)
  B2 stricturing 22 (15.1)
  B3 penetrating 21 (14.4)
  + Perianal disease 41 (28.1)
 Extent of UC, n (%)
  E1 ulcerative proctitis 4 (6.9)
  E2 left sided UC 20 (34.5)
  E3 extensive UC (pancolitis) 34 (58.6)
Current medication use, n (%)
 5-Aminosalicylate 44 (21.6)
 Steroids 10 (4.9)
 Immunomodulators 45 (22.1)
 Anti-tumor necrosis factor agents 56 (27.5)
Axial and/or peripheral joint complaints, n (%) 113 (55.4)
 Peripheral joint complaints only 41 (36.3)
 Back pain only 8 (7.1)
 Mixed complaints 64 (56.6)
Distribution of (painful) peripheral joints, n (%)
 Monoarticular 15 (14.3)
 Oligoarticular 45 (42.9)
 Polyarticular 45 (42.9)
Enthesitis,a n (%) 2 (1.0)
Dactylitis,a n (%) 2 (1.0)
Extraintestinal manifestation,b n (%) 49 (24.0)
Elevated C-reactive protein, n (%) 30 (14.7)
Elevated erythrocyte sedimentation rate, n (%) 42 (20.9)
HLA-B27, c (%) 7 (5.9)
Sacroiliitis on X-ray,d (%) 5/123 (4.1%)
aEnthesitis and dactylitis are defined in accordance to reference 26.
bSkin: psoriasis, erythema nodosum, pyoderma gangrenosum. Joints: ar-
thritis, dactylitis, heel enthesitis, ankylosing spondylitis. Eyes: acute anterior 
uveitis (current or past).
cHLA-B27 status was available in 118 patients.
dResults of X-ray were available in 123 patients.
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−2.00, −1.38), SF-36–MCS (β = −0.48, 95% CI −0.87, −0.10), work 
impairment (β = 0.22, 95% CI 0.07, 0.37), and activity impairment 
(β = 0.48, 95% CI 0.39, 0.58).
In the second step of our multivariate model we assessed whether 
the addition of illness perceptions significantly improved our first 
model, using the likelihood ratio test (difference of −2 log likeli-
hood between the two models). The addition of illness perceptions 
improved the first model for all health outcomes (p = 0.01). Illness 
consequences were significantly associated with SIBDQ (β = −0.39, 
95% CI −0.59, −0.18), SF-36–PCS (β  =  −0.59, 95% CI −0.77, 
−0.40), work impairment (β = 0.14, 95% CI 0.06, 0.22) and activity 
impairment (β = 0.13, 95% CI 0.07, 0.18), meaning that low QOL 
and work and activity impairments were associated with stronger 
beliefs that IBD will have negative consequences for the person’s life. 
Emotional representations were significantly associated with SIBDQ 
(β  = −0.47, 95% CI −0.66, −0.28), SF-36–MCS (β  = −0.72, 95% 
CI −0.93, −0.52), and activity impairment (β = 0.06, 95% CI 0.01, 
0.12), meaning that low QOL and high activity impairments were 
associated with negative beliefs about how the illness affects one’s 
emotional well-being.
In our third model we assessed whether the addition of coping 
significantly improved our second model. The addition of coping 
Table 4. Linear mixed model with work productivity and activity impairment (assessed with WPAI) as outcome variables and demographic/
clinical variables (step 1), illness perceptions (step 2), and coping (step 3) as independent variables.
Predicting variables Work productivity Activity impairment
β 95% CI β 95% CI
Step 1: demographic and clinical variables
 Gender 0.26 −0.22, 0.75
 Disease activity 0.41*** 0.29, 0.53 0.19*** 0.12, 0.25
 Joint pain 0.22** 0.07, 0.37 0.48*** 0.39, 0.58
Step 2: illness perceptions
 Identity 0.05 −0.08, 0.19 0.10* 0.01, 0.19
 Consequences 0.14** 0.06, 0.22 0.13*** 0.07, 0.18
 Personal control −0.03 −0.08, 0.02
 Illness coherence −0.08 −0.17, 0.01 0.01 −0.05, 0.07
 Timeline cyclical −0.00 −0.11, 0.10 0.02 −0.06, 0.09
 Emotional representations 0.04 −0.04, 0.12 0.06* 0.01, 0.12
Step 3: coping
 Decreasing activity 0.07 −0.02, 0.16 0.10** 0.04, 0.17
 Pacing 0.04 −0.04, 0.11 0.02 −0.03, 0.07
Results of linear mixed model showing the independent influence of predicting variables on work productivity or work impairment, represented as β coefficients. 
These coefficients refer to how many standard deviations work productivity or work impairment will change per standard deviation increase in the predicting 
variable.
WPAI, Work Productivity and Activity Impairment questionnaire.
*p < 0.05; **p < 0.01; ***p < 0.001.
Table 3. Linear mixed models with SF-36–PCS and SF-36–MCS as outcome variables and demographic/clinical variables (step 1), illness 
perceptions (step 2), and coping (step 3) as independent variables. 
Predicting variables: SF-36–PCS SF-36–MCS
β 95% CI β 95% CI
Step 1: demographic and clinical variables
 Gender – – −0.90 −2.84, 1.03
 Disease activity −0.63*** −0.84, −0.42 −0.58*** −0.84, −0.31
 Joint pain −1.69*** −2.00, −1.38 −0.48* −0.87, −0.10
Step 2: illness perceptions
 Identity −0.34* −0.62, −0.06 −0.01 −0.34, 0.31
 Consequences −0.59*** −0.77, −0.40 −0.21 −0.42, 0.00
 Personal control 0.20* 0.03, 0.37 0.09 −0.11, 0.29
 Illness coherence – – 0.30** 0.08, 0.52
 Timeline cyclical – – −0.04 −0.32, 0.23
 Emotional representations 0.08 −0.07, 0.24 −0.72*** −0.93, −0.52
Step 3: coping
 Decreasing activity −0.21* −0.41, −0.01 −0.42** −0.66, −0.18
 Pacing −0.17 −0.35, 0.00 0.23 −0.05, 0.51
 Creative solutions – – 0.03 −0.16, 0.22
Results of linear mixed model showing the independent influence of predicting variables on SF-36–PCS or SF-36–MCS, represented as β coefficients. These coef-
ficients refer to how many standard deviations SF-36–PCS or SF-36–MCS will change per standard deviation increase in the predicting variable.
*p < 0.05; **p < 0.01; ***p < 0.001.
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improved the second model across SF-36–PCS (p  =  0.00), SF-36–
MCS (p  =  0.00), and activity impairment (p  =  0.00). Decreasing 
activity was significantly associated with SIBDQ (β = −0.26, 95% CI 
−0.48, −0.03), SF-36–PCS (β = −0.21, 95% CI −0.41, −0.01), SF-36–
MCS (β  = −0.42, 95% CI −0.66, −0.18), and activity impairment 
(β = 0.10, 95% CI 0.04, 0.17). In addition, we assessed whether the 
impact of illness perceptions on health outcomes was mediated by 
particular coping strategies. Decreasing activity mediated the impact 
of illness identity and illness consequences on both SF-36–PCS and 
SF-36–MCS.
4. Discussion
In this prospective study of patients with IBD-associated arthropa-
thy, we found that back/joint pain had a negative impact on QOL 
and work productivity. This negative impact on QOL and work pro-
ductivity remained significant during a follow-up of 12 months, after 
controlling for gender and IBD activity. Additionally, the QOL and 
work productivity of IBD patients were also highly determined by 
several illness perceptions and, to a lesser extent, by coping.
To our knowledge, this is the first study to date assessing the 
impact of illness perceptions and coping on QOL and work produc-
tivity in patients with IBD-associated arthropathy.
Although QOL and work productivity were mainly determined 
by back/joint pain and activity of IBD, illness perceptions contrib-
uted significantly to the variance of these outcomes. Our findings 
are in line with previous studies in CD and UC assessing the impact 
of disease characteristics and illness perceptions on various health 
outcomes.17,18,23 In these studies, disease characteristics (mainly dis-
ease activity) contributed 49–68%20,21,26 and 23%17 of the variance 
of QOL and disability, respectively. Illness perceptions contributed 
an additional 9–21%17,18,23 and 23%17 of variance of QOL and 
disability, respectively. In this study we have demonstrated that a 
decrease in QOL was highly associated with stronger beliefs that 
IBD will have negative consequences for one’s life (i.e. illness con-
sequences), and negative beliefs about how IBD affects one’s emo-
tional well-being (i.e. emotional representations). The strong impact 
of illness consequences and emotional representations has been con-
firmed by previous studies in IBD. For instance, in a study of 80 
IBD patients it was shown that illness consequences were moder-
ately or strongly associated with different aspects of adjustment to 
their disease, including psychological distress, QOL and functional 
independence.17
We also examined whether coping added significantly to the vari-
ance of health outcomes, after controlling for gender, disease activ-
ity, and remaining illness perceptions. Coping is defined as ongoing 
cognitive or behavioral efforts to manage psychological distress.39,40 
Coping strategies (or styles) can either be active (problem-based) 
or passive (emotion-based). Active coping (creative solution seek-
ing, decreasing activities, and pacing) aims to alter or eliminate the 
source of stress, while passive coping (consideration, accepting, opti-
mism) aims to reduce the emotional distress caused by the situation. 
Patients with IBD are more likely to rely on passive coping strate-
gies.41–43 Consistent with previous evidence in IBD, we found that 
coping significantly added to the variance of QOL and impairments 
in daily activity.24,25 However, other studies in IBD did not observe 
a contributory role of coping with respect to QOL, psychological 
distress and functional independence.17,23 This may be explained 
by the fact that in these studies coping was assessed with a generic 
coping questionnaire, which tends to obscure associations between 
illness-specific coping, QOL, and activity and work impairments. 
In the present study we used the disease-specific coping question-
naire, which addresses coping strategies directed at the most impor-
tant stressors of immune-mediated inflammatory diseases, including 
pain, limitations, and dependency.
Additionally, we found that the behavioral coping strategy 
‘decreasing activities’ was negatively associated with QOL and 
activity impairments. This association has not been observed in IBD 
before. In patients with rheumatoid arthritis and ankylosing spon-
dylitis, decreasing activity has been clearly found to be negatively 
associated with QOL,44 functional status,45,46 and work productiv-
ity.47 It has been postulated that avoidance (i.e. decreasing activities) 
may have beneficial effects in the short term by facilitating healing in 
rheumatoid arthritis. However, in the long term it becomes a mala-
daptive coping strategy by limiting joint movement and inducing 
muscle weakness and disuse.48–50
Finally, we have demonstrated that the impact of illness percep-
tions, in particular illness identity and illness consequences, on QOL 
is reduced when patients do not decrease activity in order to cope with 
pain. This mediating effect supports the Common Sense Model,13,14 
which states that the impact of illness perceptions on health outcomes 
may be attenuated by adopting a particular coping strategy.
This study has several important strengths. First, all patients were 
systematically examined by a multidisciplinary team of gastroenter-
ologists and rheumatologists. Second, patients were prospectively 
followed for 12 months, which enabled us to assess the predictive 
value of back/joint pain, illness perceptions, and coping on several 
important patient-reported health outcomes. Third, the results of 
our multiple linear mixed models strongly support the well-validated 
Common Sense Model.
This study has also several limitations. First, as reflected by the 
relatively high proportion of anti-tumor necrosis factor users, our 
study included a selected patient group. Therefore, extrapolation of 
our data to the general IBD population may be limited. However, 
the primary aim of the present study was to determine associations 
between back/joint pain, illness perceptions, and coping that are also 
applicable to population-based samples. Second, attrition bias may 
have occurred due to differences between patients who did and did 
not complete the follow-up period. However, demographic and dis-
ease characteristics were similar between the two groups, except for 
the lower age of the noncompleters. We consider that this difference 
did not affect our outcomes, since age was not found to be associated 
with QOL and work productivity (Online Supplementary Material 
B). Third, as the CORS has not been validated in patients with IBD-
associated arthropathy, coping strategies directed at IBD-specific 
stressors such as abdominal pain, urgency, and diarrhea might have 
been missed. However, the CORS has been extensively validated in 
patients with rheumatoid arthritis, a comparable immune-medi-
ated inflammatory disease with regard to pathogenesis, stressors 
and treatment. Besides, IBD studies that used a generic—though 
validated—coping questionnaire failed to identify relevant coping 
strategies. Fourth, although we adjusted for the most important con-
founders, such as gender and clinical disease activity, residual con-
founding cannot be completely excluded.
If these limitations are taken into consideration, we feel that 
this prospective study provides valuable data for clinical practice. 
Arthropathies are the most common extraintestinal manifestation 
in IBD, leading to significant morbidity, disability, and societal costs. 
Recently, it has been reported that self-reported joint pain is a major 
predictor of work disability in patients with IBD.51 Work disability is 
major cost driver, accounting for 18–69% of overall costs in IBD.52,53 
Thus, adequate treatment of back/joint pain may lead to reduced 
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work disability and associated costs. Nevertheless, many patients 
with IBD-associated arthropathy remain undiagnosed.54 Apart from 
providing these patients with the appropriate medical treatment, 
their QOL and work productivity can be further improved by behav-
ioral interventions. These interventions should be aimed at eliciting 
and addressing patients’ illness perceptions and stimulating adaptive 
coping strategies. Previous studies have already shown that behav-
ioral interventions based on the Common Sense Model can change 
illness perceptions and coping strategies of patients after myocardial 
infarction and patients with end-stage renal disease, and thereby 
improve major components of QOL (e.g. return to work).55–58
In conclusion, back/joint pain persistently and negatively 
impacted the QOL and work productivity of patients with IBD-
associated arthropathy. Illness perceptions and coping also had a 
significant impact on QOL and work productivity. As potentially 
modifiable factors, illness perceptions and coping may provide addi-
tional targets for behavioral interventions, aimed at improving QOL 
and increasing work productivity. Multidisciplinary teams, incorpo-
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